XML 38 R28.htm IDEA: XBRL DOCUMENT v3.10.0.1
Collaboration Agreements - Summary of Revenue Recognized under Agreement (Detail) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]        
Total revenue $ 29,027 $ 40,550 $ 104,903 $ 100,260
License Revenue [Member]        
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]        
Total revenue 0 9,933 14,323 9,933
Development and Other Revenue [Member]        
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]        
Total revenue 29,027 30,617 90,580 90,327
Astellas Agreement [Member] | License Revenue [Member] | Japan [Member]        
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]        
Total revenue 0 0 14,323 0
Astellas Agreement [Member] | License Revenue [Member] | Europe [Member]        
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]        
Total revenue 0 0 0 0
Astellas Agreement [Member] | Development and Other Revenue [Member] | Japan [Member]        
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]        
Total revenue 474 517 2,065 1,130
Astellas Agreement [Member] | Development and Other Revenue [Member] | Europe [Member]        
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]        
Total revenue 4,658 4,805 14,384 13,976
AstraZeneca Agreements [Member] | China [Member]        
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]        
Total revenue 0 0 0 0
AstraZeneca Agreements [Member] | License Revenue [Member] | U.S./RoW [Member]        
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]        
Total revenue 0 9,933 0 9,933
AstraZeneca Agreements [Member] | Development and Other Revenue [Member] | U.S./RoW [Member]        
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]        
Total revenue $ 23,895 $ 25,295 $ 74,096 $ 75,218